Galmed Pharmaceuticals Ltd (GLMD)

Currency in USD
0.570
+0.001(+0.18%)
Closed·
0.556-0.014(-2.51%)
·
Advertisement
GLMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.5420.570
52 wk Range
0.4112.340
Key Statistics
Prev. Close
0.569
Open
0.563
Day's Range
0.542-0.57
52 wk Range
0.411-2.34
Volume
39.85K
Average Volume (3m)
3.48M
1-Year Change
-73.8532%
Book Value / Share
2.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GLMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Galmed Pharmaceuticals Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
20/05/2026
EPS / Forecast
-0.38 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare GLMD to Peers and Sector

Metrics to compare
GLMD
Peers
Sector
Relationship
P/E Ratio
−0.4x−3.2x−0.4x
PEG Ratio
−0.01−0.020.00
Price/Book
0.2x2.1x2.6x
Price / LTM Sales
-1,776.7x3.0x
Upside (Analyst Target)
-183.1%49.7%
Fair Value Upside
Unlock4.0%7.3%Unlock

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.97K0.03%1.10K
Other Institutional Investors
329.61K5.01%183.59K
Public Companies & Retail Investors
6.25M94.96%3.48M
Total
6.58M100.00%3.67M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Heights Capital Management, Inc.2.63%173,33397
Two Sigma Investments, LP1.22%80,17745

People Also Watch

0.9577
ONCO
-10.50%
0.442
CDT
+0.41%
14.2100
AKTX
-8.20%
0.44
RMSG
-4.50%

FAQ

What Is the Galmed Pharma (NASDAQ: GLMD) Share Price Today?

The Galmed Pharma stock price today is 0.570 USD.

What Stock Exchange Does Galmed Pharma (GLMD) Trade On?

Galmed Pharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Galmed Pharma?

The stock symbol (also called a 'ticker') for Galmed Pharma is "GLMD."

What Is the Current Galmed Pharma Market Capitalisation?

As of today, Galmed Pharma (NASDAQ: GLMD) market cap is 3.650M USD.

What Is Galmed Pharma's (GLMD) Earnings Per Share (TTM)?

The Galmed Pharma EPS is currently -2.391 (Trailing Twelve Months).

When Is the Next Galmed Pharma Earnings Date?

Galmed Pharma's next earnings report will be released on 30/07/2026.

Is GLMD a Buy or Sell From a Technical Analyst Perspective?

Based on today's Galmed Pharma moving averages and other technical indicators, the daily buy/sell signal for GLMD stock is Strong Sell.

How Many Times Has Galmed Pharma Stock Split?

Galmed Pharma has split 2 times. (See the GLMD stock split history page for full effective split date and price information.)

How Many Employees Does Galmed Pharma Have?

Galmed Pharma has 5 employees, based on their latest Companies House report.

What is the current trading status of Galmed Pharma (NASDAQ: GLMD)?

As of 09/07/2026, Galmed Pharma (GLMD) is trading at a share price of 0.570 USD, with a previous close of 0.569 USD. The stock has fluctuated within a day range of 0.542 USD to 0.570 USD, while its 52-week range spans from 0.411 USD to 2.340 USD.

What Is the GLMD Premarket Price?

GLMD's last pre-market stock price is 0.575 USD. The pre-market share volume is 8,230.000, and the stock has decreased by 0.006, or 1.050%.

What Is the GLMD After Hours Price?

GLMD's last after hours stock price is 0.556 USD, the stock has decreased by -0.014, or -2.510%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.